KHAWAR CHAUDHRY: Open Payments
NPI 1538422548 · WAYNE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 31 payments from 12 companies in 2025. Trend: 2023 $748 · 2024 $349 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 6 | $136 |
| Indivior Inc. | 5 | $86 |
| ABBVIE INC. | 4 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $71 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Braeburn Inc. | 2 | $39 |
| UCB, Inc. | 2 | $36 |
| Alkermes, Inc. | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
Products named: SUBLOCADE, CAPLYTA, VRAYLAR, Auvelity, BRIXADI, Nayzilam, VIVITROL, MAVYRET.
Industry payments across MI — which companies pay providers there.
